Nuvation Bio

Pharmaceutical ManufacturingNew York, United States201-500 Employees

Nuvation Bio is a global oncology-focused biopharma company pursuing therapies for difficult-to-treat cancers, with the aim of delivering meaningful benefits to patients. Its pipeline includes a next-generation ROS1 inhibitor, a brain-penetrant IDH1 inhibitor, and an innovative drug-drug conjugate program. The company concentrates on advancing targeted and innovative cancer therapies to broaden treatment options where current options are limited.

Based in New York City, with additional offices in San Francisco, Boston, and Shanghai, it operates within the pharmaceutical manufacturing and development landscape. Nuvation Bio was founded in 2018 by David Hung, a veteran of the biopharma industry. In 2026, the company announced a manufacturing partnership with Thermo Fisher Scientific to produce ibtrozi for lung cancer.

Sign up for free to view info

Email Format Employee directory